IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): IMPACT OF THE YOU&I™ PATIENT SUPPORT PROGRAM ON TREATMENT ADHERENCE
(Abstract release date: 05/19/16)
EHA Library. Peters A. 06/09/16; 132628; E1079
Dr. Anthea Peters
Contributions
Contributions
Abstract
Abstract: E1079
Type: Eposter Presentation
Background
Oral therapies for cancer can present several advantages over intravenous drugs, including greater flexibility and convenience for the patient and reduced healthcare costs. However, for treatment to be effective, a high degree of adherence must be maintained. Prior studies have shown a range of non-adherence to long-term oral anticancer therapy, with adherence rates varying considerably with patient characteristics. Consequences of low adherence can include increased healthcare costs and inferior patient outcomes, including decreased time to relapse and decreased survival. The YOU&i™ Patient Support Program (PSP) supports patients with reimbursement services and provides patients and their physicians with a comprehensive nurse-coaching program in an effort to encourage treatment adherence.
Aims
To examine patient satisfaction and adherence to ibrutinib within the YOU&i™ PSP.
Methods
Using evidence-based literature reviews and global/local market research, barriers to treatment adherence were identified. These included a lack of disease/treatment education, high financial burden, negative psychosocial/motivational factors, poor medication routine-building, and suboptimal patient:physician communication. Each patient’s risk for non-adherence was calculated using the Morisky Medication Adherence Scale© score and the total number of barriers identified at initial assessment, and the frequency of nurse-coaching calls was adjusted accordingly. Patients were categorized as “adherent” if they had ≥85% compliance (obtained refills within 4 days of expected refill date) and as “discontinued” if ibrutinib was not dispensed for ≥3 months, if the patient was confirmed as discontinued prior to ibrutinib not being dispensed for ≥3 months, or if the patient was confirmed as deceased. All other patients were categorized as “partially adherent”. Patient questionnaires were used to gauge satisfaction with the YOU&i™ PSP.
Results
As of January 19, 2016, a total of 903 CLL patients were enrolled in the PSP; 87% of patients opted in for nurse coaching. Most patients (58%) had received 1-2 prior lines of therapy. At 9 months from treatment initiation, 81% of patients who received nurse coaching vs 59% of those who did not were categorized as “adherent” (excludes patients who discontinued due to disease progression or death). Similarly, only 7% of those who received nurse coaching vs 23% of those who did not were discontinued from ibrutinib for reasons other than disease progression or death. In the overall PSP population, 17% discontinued the program; among the patients discontinuing, the most common reason was death (49%). Overall, 91% of patients reported that they were satisfied/very satisfied with the PSP, with 87% likely to recommend the program. Furthermore, 78% reported that the PSP was very helpful in supporting their adherence to ibrutinib.
Conclusion
Although there is an inherent potential for self-selection bias, these results from the YOU&i™ PSP suggest that nurse coaching may contribute to improved patient adherence to oral anticancer treatment. In the YOU&i™ PSP, nurse coaching appeared to also be associated with decreased treatment discontinuation. This program, or similar supportive programs, may be helpful in assisting patients in maintaining adherence to treatment with ibrutinib.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Treatment
Type: Eposter Presentation
Background
Oral therapies for cancer can present several advantages over intravenous drugs, including greater flexibility and convenience for the patient and reduced healthcare costs. However, for treatment to be effective, a high degree of adherence must be maintained. Prior studies have shown a range of non-adherence to long-term oral anticancer therapy, with adherence rates varying considerably with patient characteristics. Consequences of low adherence can include increased healthcare costs and inferior patient outcomes, including decreased time to relapse and decreased survival. The YOU&i™ Patient Support Program (PSP) supports patients with reimbursement services and provides patients and their physicians with a comprehensive nurse-coaching program in an effort to encourage treatment adherence.
Aims
To examine patient satisfaction and adherence to ibrutinib within the YOU&i™ PSP.
Methods
Using evidence-based literature reviews and global/local market research, barriers to treatment adherence were identified. These included a lack of disease/treatment education, high financial burden, negative psychosocial/motivational factors, poor medication routine-building, and suboptimal patient:physician communication. Each patient’s risk for non-adherence was calculated using the Morisky Medication Adherence Scale© score and the total number of barriers identified at initial assessment, and the frequency of nurse-coaching calls was adjusted accordingly. Patients were categorized as “adherent” if they had ≥85% compliance (obtained refills within 4 days of expected refill date) and as “discontinued” if ibrutinib was not dispensed for ≥3 months, if the patient was confirmed as discontinued prior to ibrutinib not being dispensed for ≥3 months, or if the patient was confirmed as deceased. All other patients were categorized as “partially adherent”. Patient questionnaires were used to gauge satisfaction with the YOU&i™ PSP.
Results
As of January 19, 2016, a total of 903 CLL patients were enrolled in the PSP; 87% of patients opted in for nurse coaching. Most patients (58%) had received 1-2 prior lines of therapy. At 9 months from treatment initiation, 81% of patients who received nurse coaching vs 59% of those who did not were categorized as “adherent” (excludes patients who discontinued due to disease progression or death). Similarly, only 7% of those who received nurse coaching vs 23% of those who did not were discontinued from ibrutinib for reasons other than disease progression or death. In the overall PSP population, 17% discontinued the program; among the patients discontinuing, the most common reason was death (49%). Overall, 91% of patients reported that they were satisfied/very satisfied with the PSP, with 87% likely to recommend the program. Furthermore, 78% reported that the PSP was very helpful in supporting their adherence to ibrutinib.
Conclusion
Although there is an inherent potential for self-selection bias, these results from the YOU&i™ PSP suggest that nurse coaching may contribute to improved patient adherence to oral anticancer treatment. In the YOU&i™ PSP, nurse coaching appeared to also be associated with decreased treatment discontinuation. This program, or similar supportive programs, may be helpful in assisting patients in maintaining adherence to treatment with ibrutinib.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Treatment
Abstract: E1079
Type: Eposter Presentation
Background
Oral therapies for cancer can present several advantages over intravenous drugs, including greater flexibility and convenience for the patient and reduced healthcare costs. However, for treatment to be effective, a high degree of adherence must be maintained. Prior studies have shown a range of non-adherence to long-term oral anticancer therapy, with adherence rates varying considerably with patient characteristics. Consequences of low adherence can include increased healthcare costs and inferior patient outcomes, including decreased time to relapse and decreased survival. The YOU&i™ Patient Support Program (PSP) supports patients with reimbursement services and provides patients and their physicians with a comprehensive nurse-coaching program in an effort to encourage treatment adherence.
Aims
To examine patient satisfaction and adherence to ibrutinib within the YOU&i™ PSP.
Methods
Using evidence-based literature reviews and global/local market research, barriers to treatment adherence were identified. These included a lack of disease/treatment education, high financial burden, negative psychosocial/motivational factors, poor medication routine-building, and suboptimal patient:physician communication. Each patient’s risk for non-adherence was calculated using the Morisky Medication Adherence Scale© score and the total number of barriers identified at initial assessment, and the frequency of nurse-coaching calls was adjusted accordingly. Patients were categorized as “adherent” if they had ≥85% compliance (obtained refills within 4 days of expected refill date) and as “discontinued” if ibrutinib was not dispensed for ≥3 months, if the patient was confirmed as discontinued prior to ibrutinib not being dispensed for ≥3 months, or if the patient was confirmed as deceased. All other patients were categorized as “partially adherent”. Patient questionnaires were used to gauge satisfaction with the YOU&i™ PSP.
Results
As of January 19, 2016, a total of 903 CLL patients were enrolled in the PSP; 87% of patients opted in for nurse coaching. Most patients (58%) had received 1-2 prior lines of therapy. At 9 months from treatment initiation, 81% of patients who received nurse coaching vs 59% of those who did not were categorized as “adherent” (excludes patients who discontinued due to disease progression or death). Similarly, only 7% of those who received nurse coaching vs 23% of those who did not were discontinued from ibrutinib for reasons other than disease progression or death. In the overall PSP population, 17% discontinued the program; among the patients discontinuing, the most common reason was death (49%). Overall, 91% of patients reported that they were satisfied/very satisfied with the PSP, with 87% likely to recommend the program. Furthermore, 78% reported that the PSP was very helpful in supporting their adherence to ibrutinib.
Conclusion
Although there is an inherent potential for self-selection bias, these results from the YOU&i™ PSP suggest that nurse coaching may contribute to improved patient adherence to oral anticancer treatment. In the YOU&i™ PSP, nurse coaching appeared to also be associated with decreased treatment discontinuation. This program, or similar supportive programs, may be helpful in assisting patients in maintaining adherence to treatment with ibrutinib.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Treatment
Type: Eposter Presentation
Background
Oral therapies for cancer can present several advantages over intravenous drugs, including greater flexibility and convenience for the patient and reduced healthcare costs. However, for treatment to be effective, a high degree of adherence must be maintained. Prior studies have shown a range of non-adherence to long-term oral anticancer therapy, with adherence rates varying considerably with patient characteristics. Consequences of low adherence can include increased healthcare costs and inferior patient outcomes, including decreased time to relapse and decreased survival. The YOU&i™ Patient Support Program (PSP) supports patients with reimbursement services and provides patients and their physicians with a comprehensive nurse-coaching program in an effort to encourage treatment adherence.
Aims
To examine patient satisfaction and adherence to ibrutinib within the YOU&i™ PSP.
Methods
Using evidence-based literature reviews and global/local market research, barriers to treatment adherence were identified. These included a lack of disease/treatment education, high financial burden, negative psychosocial/motivational factors, poor medication routine-building, and suboptimal patient:physician communication. Each patient’s risk for non-adherence was calculated using the Morisky Medication Adherence Scale© score and the total number of barriers identified at initial assessment, and the frequency of nurse-coaching calls was adjusted accordingly. Patients were categorized as “adherent” if they had ≥85% compliance (obtained refills within 4 days of expected refill date) and as “discontinued” if ibrutinib was not dispensed for ≥3 months, if the patient was confirmed as discontinued prior to ibrutinib not being dispensed for ≥3 months, or if the patient was confirmed as deceased. All other patients were categorized as “partially adherent”. Patient questionnaires were used to gauge satisfaction with the YOU&i™ PSP.
Results
As of January 19, 2016, a total of 903 CLL patients were enrolled in the PSP; 87% of patients opted in for nurse coaching. Most patients (58%) had received 1-2 prior lines of therapy. At 9 months from treatment initiation, 81% of patients who received nurse coaching vs 59% of those who did not were categorized as “adherent” (excludes patients who discontinued due to disease progression or death). Similarly, only 7% of those who received nurse coaching vs 23% of those who did not were discontinued from ibrutinib for reasons other than disease progression or death. In the overall PSP population, 17% discontinued the program; among the patients discontinuing, the most common reason was death (49%). Overall, 91% of patients reported that they were satisfied/very satisfied with the PSP, with 87% likely to recommend the program. Furthermore, 78% reported that the PSP was very helpful in supporting their adherence to ibrutinib.
Conclusion
Although there is an inherent potential for self-selection bias, these results from the YOU&i™ PSP suggest that nurse coaching may contribute to improved patient adherence to oral anticancer treatment. In the YOU&i™ PSP, nurse coaching appeared to also be associated with decreased treatment discontinuation. This program, or similar supportive programs, may be helpful in assisting patients in maintaining adherence to treatment with ibrutinib.
Session topic: E-poster
Keyword(s): Chronic lymphocytic leukemia, Treatment
{{ help_message }}
{{filter}}